MedPath

湖北潜江制药股份有限公司

Ownership
-
Established
2009-09-18
Employees
-
Market Cap
-
Website
www.qjzy.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

114

NMPA:114

Drug Approvals

Ceftazidime for Injection

Product Name
强奇
Approval Number
国药准字H20093740
Approval Date
Jan 12, 2024
NMPA

Ceftazidime for Injection

Product Name
强奇
Approval Number
国药准字H20093737
Approval Date
Jan 12, 2024
NMPA

Cefuroxime Sodium for Injection

Product Name
注射用头孢呋辛钠
Approval Number
国药准字H20093743
Approval Date
Jan 3, 2024
NMPA

Cefuroxime Sodium for Injection

Product Name
注射用头孢呋辛钠
Approval Number
国药准字H20093742
Approval Date
Jan 3, 2024
NMPA

Ribavirin Tablets

Product Name
利巴韦林片
Approval Number
国药准字H19993454
Approval Date
Sep 23, 2022
NMPA

Diclofenac Sodium Suppositories

Product Name
双氯芬酸钠栓
Approval Number
国药准字H42020273
Approval Date
Dec 15, 2021
NMPA

Sodium Cromoglicate Eye Drops

Product Name
色甘酸钠滴眼液
Approval Number
国药准字H20065124
Approval Date
Jan 25, 2021
NMPA

Lincomycin Hydrochloride Eye Drops

Product Name
盐酸林可霉素滴眼液
Approval Number
国药准字H20065135
Approval Date
Jan 25, 2021
NMPA

Hydrobenzole Hydrochloride Eye Drops

Product Name
盐酸羟苄唑滴眼液
Approval Number
国药准字H20065134
Approval Date
Jan 25, 2021
NMPA

珍珠明目滴眼液

Approval Number
国药准字Z20063994
Approval Date
Jan 25, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.